Navigation Links
Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations
Date:6/18/2009

TORONTO, June 18 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), is pleased to announce that Ms. Laura Agensky has been appointed Vice-President of Clinical Operations. Since joining Transition in 2001, Ms. Agensky has managed the execution of all the Company's clinical trials across a diverse set of disease indications including Alzheimer's disease and diabetes. Prior to Transition, she served in multiple clinical development roles at large pharmaceutical, biotechnology and consulting organizations. As Vice-President, Ms. Agensky will continue to lead Transition's clinical operations group.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally or developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.


'/>"/>
SOURCE Transition Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medicare, NW Denver Partners Launch Care Transitions Project
2. Digital TV Transition Coming Soon; Update Preparedness Plans
3. Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results
4. Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2009 Financial Results on Wednesday, May 13th, at 4:30 P.M. EST
5. TouchPointCare Introduces TPC Transition Home to Help Hospitals Reduce Unplanned Readmissions
6. Transition From Home to Hospital Rarely Seamless
7. iMedica Launches Transition™, a New, Streamlined EHR That Breaks Down the Barriers to Physician Adoption and Use
8. HCSC Discusses the Controversial ICD-10 Transition at the 2009 HIMSS Conference
9. The Quantum Group Announces Transition to Continental Stock Transfer
10. iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice
11. iMedica and Imagetek Team Up to Ease Transition to Paperless Medical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... ... NexTec Group has been selected as a member of the Bob Scott’s VAR ... field of midmarket financial software. , Members of the VAR Stars were selected based ... on revenue and those firms chosen represent a wide range of size and many ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... Outreach is a program that strives to better communities around the world by ... community. It also provides the opportunity for team members to become involved in ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation ... achieved accreditation for its specialty care services. Albertsons Companies is the largest ... care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication ...
(Date:1/15/2017)... Santa Rosa, CA (PRWEB) , ... January 15, ... ... to nominate their choice of best physicians in eight Bay Area counties for ... selected by the healthcare research company managing the award process. Results were announced ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock ... Pennsylvania. As construction wraps up on the 14,000+ square foot climbing gym, the owners ... location, including three in New Jersey and two in New York. With this being ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... 2017 Eli Lilly and Company (NYSE: ... INCY ) announced today that the U.S. Food and ... the new drug application (NDA) for investigational baricitinib, a ... severe rheumatoid arthritis (RA). The NDA for baricitinib was ... The FDA extended the action date to allow time ...
(Date:1/13/2017)... -- Wichita Laser Clinic at Healthy Life ... Wichita, Kansas featuring the Astanza Revolution ... rejuvenation, getting rid of unwanted tattoos, killing toenail fungus, ... "Since being in the aesthetics industry, I have ... for laser tattoo removal and other popular cosmetic ...
(Date:1/13/2017)... , Jan. 12, 2017   JDRF ... diabetes (T1D) research, is pleased to announce that ... the Centers for Medicare & Medicaid Services (CMS) ... by the FDA for use in making diabetes ... step toward making them eligible for coverage under ...
Breaking Medicine Technology: